As TIGIT is highly expressed in HCC, and is a new immunotherapeutic target that may be regulated by RT (33), we introduced 125I seed implantation into the tumor for brachytherapy and regulated the expression of TIGIT. Here, TIGIT is linked to hepatocellular carcinoma.